Role of Plasma Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 and microRNA-98 in Severity and Risk of Coronary Artery Disease

Background: Coronary artery diseases are the most important cause of premature death, and these diseases are predominantly related to atherosclerosis. Soluble lectin-like oxidized low-density lipoprotein receptor-1 and microRNAs are closely associated with atherosclerotic coronary heart diseases.Aims: To investigate the relationship between the severity and risk of coronary artery disease and plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 and miR-98.Study Design: Case-control study.Methods: Angiographically documented patients with 38 single-vessel, 75 double-vessel, and 62 multi-vessel coronary artery disease; 62 healthy control participants; and 24-hour hypoxic (1% oxygen) human umbilical vein endothelial cells were included in this study. Circulating soluble lectin-like oxidized low-density lipoprotein receptor-1 concentrations were determined through enzyme-linked immunosorbent assays, and miR-98 expressions were measured by quantitative real-time polymerase chain reaction.Results: The expressions of plasma soluble lectin-like oxidized low-density lipoprotein receptor-1 levels were progressively and significantly higher in patients with single-vessel, double-vessel, and multi-vessel coronary artery disease than in healthy controls (p

PDF

___

1. Salim SV, Alvaro A, Emelia JB, Marcio SB, Clifton WC, April PC, et al. Heart Disease and Stroke Statistics-2020 Update: A Report from the American Heart Association. Circulation 2020;141:e139-e596. [Crossref]
2. Juhani K, William W, Antti S, Davide C, Emanuele B, Christian F, et al. 2019 ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes. Eur Heart J 2020;41:407-77. [Crossref]
3. Kunming T, Sayoko O, Peter J L, Suo WX, Tatsuya S. Targeting LOX-1 in Atherosclerosis and Vasculopathy: Current Knowledge and Future Perspectives. Ann N Y Acad Sci 2019;1443:34-53. [Crossref]
4. Ajoe JK, Sri HK, Jawahar LM. Role of Ox-LDL and LOX-1 in Atherogenesis. Curr Med Chem 2019;26:1693-700. [Crossref]
5. Sanjiv S, Avtar SG. Upregulated LOX-1 Receptor: Key Player of the Pathogenesis of Atherosclerosis. Curr Atheroscler Rep 2019;21:38. [Crossref]
6. Zufeng D, Shijie L, Xian W, Xiaoyan D, Yubo F, Jiwani S, et al. Cross-talk Between LOX-1 and PCSK9 in Vascular Tissues. Cardiovasc Res 2015;107:556-67. [Crossref]
7. Naga VKP, Sotirios KK, Zufeng D, Arockiasamy A, Kottayil IV, Jawahar LM. LOX-1 in Atherosclerosis and Myocardial Ischemia: Biology, Genetics, and Modulation. J Am Coll Cardiol 2017;69:2759-68. [Crossref]
8. Martine P, Robert D, Alexis B. Scavenger Receptor LOX1 Genotype Predicts Coronary Artery Disease in Patients with Familial Hypercholesterolemia. Can J Cardiol 2017;33:1312-8. [Crossref]
9. Valter L, Alessandro P, Irene T, Simona S, Serena P, Sergio B, et al. Emerging Biomarkers of Oxidative Stress in Acute and Stable Coronary Artery Disease: Levels and Determinants. Antioxidants (Basel) 2019;8:115. [Crossref]
10. Anja H, Coy B, Steffen W, Christian R, Henning M. Soluble LOX-1: A Novel Biomarker in Patients with Coronary Artery Disease, Stroke, and Acute Aortic Dissection? J Am Heart Assoc 2020;9:e013803. [Crossref]
11. AnSheng L, YuChen W, ShihSheng C, PingHang L, ChiaMing C, Jonathan L, et al. Detection of a High Ratio of Soluble to Membrane-Bound LOX-1 in Aspirated Coronary Thrombi from Patients with ST-Segment-Elevation Myocardial Infarction. J Am Heart Assoc 2020;9:e014008. [Crossref]
12. Alexey C, Volha S, Andrey G, Varvara O, Alexander O. MicroRNAs as Potential Biomarkers in Atherosclerosis. Int J Mol Sci 2019;20:5547. [Crossref]
13. Sri HK, Joseph I, Kameel K, Hongyu G, Yunlong L, Todd CS, et al. Next Generation MicroRNA Sequencing to Identify Coronary Artery Disease Patients at Risk of Recurrent Myocardial Infarction. Atherosclerosis 2018; 278:232-9. [Crossref]
14. Sheikh SA. Diagnostic Role of Plasma MicroRNA-21 in Stable and Unstable Angina Patients and Association with Aging. Cardiol Res Pract 2020;2020:9093151. [Crossref]
15. Lei X, Gang Z, Hong Z, Shijun W, Aijun S, Yunzeng Z, et al. Peroxisome Proliferator-Activated Receptor-γ Antagonizes LOX-1-Mediated Endothelial Injury by Transcriptional Activation of miR-590-5p. PPAR Res 2019;2019:2715176. [Crossref]
16. Yao D, Xiaoqin W, Dongsheng D, Jun L, Jawahar LM. MicroRNA-98 Regulates Foam Cell Formation and Lipid Accumulation Through Repression of LOX-1. Redox Biol 2018; 16:255-62. [Crossref]
17. Shiwen Y, Chun T, Dongying C, Fangfei L, Mingcheng H, Jinghua Y, et al. miR-98 Modulates Cytokine Production from Human PBMCs in Systemic Lupus Erythematosus by Targeting IL-6 mRNA. J Immunol Res 2019;2019:9827574. [Crossref]
18. ZiWen Z, XueLi Z, YuKun L, ChaoGui L, LiangLong C. Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein receptor-1 Levels Are Associated with Angiographic Coronary Lesion Complexity in Patients with Coronary Artery Disease. Clin Cardiol 2011;34:172-7. [Crossref]
19. Valter L, Serena DT, Giuseppina N, Pietro DC, Giuseppina B. Circulating Levels of Lectin-Like Oxidized Low-Density Lipoprotein receptor-1 Are Associated with Inflammatory Markers. Lipids 2008;43:945-50. [Crossref]
20. Mehmet B, Ahmet C, MA Kobat. Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein receptor-1 Levels Are Associated with Proximal/Middle Segment of the LAD Lesions in Patients with Stable Coronary Artery Disease. Clin Res Cardiol 2012;101:247-53. [Crossref]
21. Nobutaka I, Tomonori O, Yoshihiro K, Yoshiko F, Yuko S, Mamoru N, et al. LOX Index, A Novel Predictive Biochemical Marker for Coronary Heart Disease and Stroke. Clin Chem 2010;56:550-8. [Crossref]
22. Noriaki K, Hirokazu M, Kazutaka H, Masaru T, Goro K, Toru K. Soluble Lectin-Like Oxidized LDL receptor-1 (sLOX-1) as A Sensitive and Specific Biomarker for Acute Coronary Syndrome--Comparison with Other Biomarkers. J Cardiol 2010; 56:159-65. [Crossref]
23. ZiWen Z, YiWei X, ShuMei L, JinJian G, JianMin S, JuChang H, et al. Baseline Serum sLOX-1 Concentrations Are Associated With 2-Year Major Adverse Cardiovascular and Cerebrovascular Events in Patients After Percutaneous Coronary Intervention. Dis Markers 2019;2019:4925767. [Crossref]
24. Junfeng L, Yunde L, Kegang J, Zhixiao H, Qianyu H, Zhili L, et al. Clinical Analysis of Lectin-Like Oxidized Low-Density Lipoprotein receptor-1 in Patients with in-Stent Restenosis After Percutaneous Coronary Intervention. Medicine (Baltimore) 2018;97:e0366. [Crossref]
25. Andreas S, Antonios K, Stauros S, Maria G, George L, Konstantinos T, et al. Expression of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Human Epicardial and Intramyocardial Coronary Arteries of Male Patients Undergoing Coronary Artery Bypass Grafting. Cardiology 2018;139:203-7. [Crossref]
26. Nicole S, ChihChieh C, LiangYin K, ChihSheng C, Jonathan L, Tatsuya S, et al. Interplay between CRP, Atherogenic LDL, and LOX-1 and Its Potential Role in the Pathogenesis of Atherosclerosis. Clin Chem 2016;62:320-7. [Crossref]
27. Jingye D, Hui W, Yuewei W. MiR-98-5p May Be A Biomarker for Screening Bronchial Asthma in Children by Targeting IL-13. Clin Lab 2019; 65. [Crossref]
28. Zhibo C, Mian W, Qiong H, Zilun L, Yang Z, Wenjian W, et al. MicroRNA-98 Rescues Proliferation and Alleviates ox-LDL-induced Apoptosis in HUVECs by Targeting LOX-1. Exp Ther Med 2017;13:1702-10. [Crossref]
29. Chuan S, Huibin L, Jing G, Yang Y, Di Y, Fang H, et al. MicroRNA-98 Negatively Regulates Myocardial Infarction-Induced Apoptosis by Down-Regulating Fas and caspase-3. Sci Rep 2017;7:7460. [Crossref]